Trials / Completed
CompletedNCT01832415
First Line Ovarian Cancer Treatment - Cohort Study
Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Detailed description
Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | Observation of bevacizumab administration in first line ovarian cancer treatment |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-02-01
- Completion
- 2016-03-01
- First posted
- 2013-04-16
- Last updated
- 2016-03-17
Locations
14 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01832415. Inclusion in this directory is not an endorsement.